| HOME >> BIOLOGY >> TECHNOLOGY |
Second Quarter Fiscal Year 2008 Corporate Highlights
-- The Company is continuing the clinical development of its lead product
candidate, VIAject(TM), an ultra rapid-acting injectable meal-time
insulin for use by patients with Type 1 or Type 2 diabetes.
VIAject(TM) is currently being tested in two pivotal Phase III clinical
trials. Enrollment for both Phase III studies was completed in
December 2007 and the last patient visit is expected in July 2008. The
Company expects to announce top line data late in the third or early in
the fourth calendar quarter of 2008 and to submit a New Drug
Application to the FDA for the complete suite of VIAject(TM) products
by the end of 2008.
-- On February 12, 2008, the Company completed a follow-on public offering
of 3,260,000 shares of its common stock at a price to the public of
$15.50 per share. The Company received net proceeds from this
offering, after deducting underwriting discounts and commissions and
expenses, of $46.8 million. The Company intends to use the net
proceeds that it received from this offering to fund the continued
development and commercialization of VIAject(TM), to develop its other
product candidates and for working capital, additional capital
expenditures and other general corporate purposes.
Conference Call and Webcast Information
Biodel's senior management will host a conference call on Friday, May
9, 2008 at 8:30 a.m., Eastern Time, to discuss these financial results and
provide a company update. Live audio of the conference call will be
available to investors, members of the news media and the general public by
dialing 1-877-545-1488 (United States) or 1-719-325-4856 (international).
To access the call by live webcast, please log on to the Investor section
of Biodel's website at
| SOURCE Biodel Inc. Copyright©2008 PR Newswire. All rights reserved |